Fulgent Genetics (NASDAQ:FLGT) Hits New 12-Month Low – Should You Sell?

Fulgent Genetics, Inc. (NASDAQ:FLGT)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as $18.86 and last traded at $18.88, with a volume of 55579 shares. The stock had previously closed at $19.18.

Fulgent Genetics Stock Down 1.3 %

The stock has a 50-day simple moving average of $21.61 and a two-hundred day simple moving average of $21.44. The firm has a market cap of $566.46 million, a PE ratio of -3.44 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The firm had revenue of $71.03 million for the quarter, compared to analysts’ expectations of $69.07 million. During the same quarter last year, the business earned ($0.33) earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Research analysts expect that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current year.

Insider Buying and Selling at Fulgent Genetics

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total value of $52,805.79. Following the transaction, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 4,324 shares of company stock worth $98,717. 31.76% of the stock is owned by insiders.

Institutional Investors Weigh In On Fulgent Genetics

Institutional investors and hedge funds have recently modified their holdings of the stock. Asset Dedication LLC purchased a new position in Fulgent Genetics in the second quarter worth about $33,000. nVerses Capital LLC purchased a new position in Fulgent Genetics during the second quarter valued at approximately $43,000. Signaturefd LLC lifted its stake in shares of Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Fulgent Genetics in the 2nd quarter valued at about $63,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Fulgent Genetics in the first quarter valued at approximately $178,000. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.